Introduction: What they say
A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, New South Wales 2052, Australia shows that “A conserved NAD+ binding pocket that regulates protein-protein interactions during aging.” This research paper was published, in the 24 March 2017 issue of the journal “Science“ [One of the best research journals in Science with an I.F of 34+], by Prof. David A. Sinclair, Jun Li, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Probiotics as biological drugs: Repurposing the Probiotic Verrucomicrobia Akkermansia Muciniphila into a longevity/healthspan-promoting bio-drug: Probiotic Verrucomicrobia Akkermansia Muciniphila inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene
What is known?
Prof. David A. Sinclair’s research team has recently shown that: (a) increased levels of NAD+ (found in non-aged tissues) inhibits the interaction the between DBC1 (deleted in breast cancer 1) and PARP1 [poly(adenosine diphosphate–ribose) polymerase]; and promotes DNA repair; (b) decreased levels of NAD+ (found in aged tissues) promotes the interaction between DBC1 and PARP1 and inhibits DNA repair; (c) aged cells/tissues that are low in NAD+ are radiation-sensitive, cancer-prone and prone to accelerated ageing; and (d) ageing-associated diseases can be reversed by increasing the concentration of NAD+ in ageing tissues, suggesting that ageing-associated diseases, in part, can be reversed by NAD+ supplementation in older animals.
From research findings to therapeutic opportunity:
This study suggests a Probiotic-based therapy for both ageing-associated diseases and life-span extension. Probiotic Verrucomicrobia Akkermansia Muciniphila, by decreasing the expression of its target gene, it may increase the levels of NAMPT and NMN/NAD+. Thereby, it may: (1) increase plasma NMN levels and tissue NAD+ availability; (2) inhibit the interaction between DBC1 and PARP1; (3) augment PARP1’s DNA repair activity; (4) protect against radiation; (5) protect against cancer; and (6) prevent age-associated gene expression pattern and accelerated ageing.
Figure 1. Probiotic Verrucomicrobia Akkermansia Muciniphila functions an anti-aging and a longevity-promoting agent. Probiotic Verrucomicrobia Akkermansia Muciniphila, by increasing NAD+ levels, may suppress ageing-associated overall physiological decline, ageing-associated diseases and improve health/lifespan
Figure 2. Probiotic Verrucomicrobia Akkermansia Muciniphila promotes health/lifespan by increasing the levels of NAD+
Figure 3. Probiotics as biological drugs: Repurposing the Probiotic Verrucomicrobia Akkermansia Muciniphila into a longevity/healthspan-promoting bio-drug. Probiotic Verrucomicrobia Akkermansia Muciniphila restores NAD+ levels, promotes DNA repair activity, attenuates ageing-associated features and promotes health/lifespan
Figure 4. Probiotic Verrucomicrobia Akkermansia Muciniphila, by increasing NAD+ levels and the PARP-1-mediated DNA repair activity, promotes/extends health/lifespan. Evidently, Centenarians (long-lived humans) have much higher levels of Probiotic Verrucomicrobia Akkermansia Muciniphila in their gut than human progeria (characterized by premature ageing) patients.
Figure 5. While restoring NAD+ levels attenuate ageing features and promote DNA repair activity, Probiotic Verrucomicrobia Akkermansia Muciniphila promotes health/lifespan by increasing PARP1-mediated DNA activity, the levels of NAD+, and by decreasing DBC1.
Thus, pharmacological formulations encompassing “Probiotic Verrucomicrobia Akkermansia Muciniphila or its genetically modified version, either alone or in combination with other probiotics,” can be used to suppress age-associated overall physiological decline and improve/extend health/lifespan.
In conclusion, this study suggests, for the first time, with detailed mechanistic insights, that Probiotic Verrucomicrobia Akkermansia Muciniphila can extend healthspan and lifespan, and therefore, will serve as a lifespan/healthspan-promoting drug.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does Probiotic Verrucomicrobia Akkermansia Muciniphila increase the levels of NMN/NAD?
Amount: $1, 500#
* Research cooperation
For purchase and payment details, you may reach us at info@genomediscovery.org
References:
Citation: Boominathan, L., Probiotics as biological drugs: Repurposing the Probiotic Verrucomicrobia Akkermansia Muciniphila into a longevity/healthspan-promoting bio-drug: Probiotic Verrucomicrobia Akkermansia Muciniphila inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 30/July/2019, 8.38 am, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org or http://newbioideas.com
Courtesy: When you cite us, kindly drop us a line at info@genomediscovery.org